At-home LED masks have six randomised trials behind them, and they show a real effect

Red and blue LED devices sold for home use do reduce acne lesions in randomised trials — and the entire evidence base is six studies with 216 people in them. That combination, a genuine effect resting on a very small literature, is unusual in consumer skincare and worth stating precisely, because it is neither the "clinically proven" of the advertising nor the "no evidence" of the sceptics.

What the review found

A systematic review and meta-analysis published in JAMA Dermatology searched for randomised trials of portable or at-home red or blue LED devices reporting change in lesion count or Investigator Global Assessment. After removing duplicates, 440 references were screened and six met the inclusion criteria [s1].

Those six covered 216 participants aged 12 to 50 with mild to moderate acne [s1]. Blue-light devices operated between 414 and 445 nanometres, red-light devices between 630 and 670 [s1]. Study durations ranged from two days to 12 weeks [s1]. Four of the six were judged at low risk of bias [s1].

Pooled with a random-effects model, LED devices produced a greater percent change than control in inflammatory lesions (45.3%, 95% confidence interval 25.1% to 65.5%, across five studies), in non-inflammatory lesions (47.7%, 18.0% to 77.4%, four studies) and in Investigator Global Assessment (45.7%, 29.1% to 62.4%, four studies) [s1]. Heterogeneity was moderate for the inflammatory-lesion and global-assessment estimates and high for non-inflammatory lesions, at 83.22% [s1]. Improvement was typically noted after four to 12 weeks of use [s1].

Red, blue and combination devices were all found efficacious, and where one trial compared blue light alone against red and blue in combination, the combination produced greater improvement in lesions and clearance [s1].

What the control groups were

The comparators are where a reader should slow down. Across the six trials they were: white light, no light at all, a sham device, and in one case benzoyl peroxide [s1]. Three of the six used a sham or an inert light source; the others used no treatment, which cannot separate a device effect from the effect of a twice-daily facial routine.

Two of the six compared LED with an active acne treatment. One found greater rates of global assessment improvement with LED than with benzoyl peroxide, and another found greater reductions in inflammatory lesions with LED than with benzoyl peroxide [s1]. Those are two small studies, not a demonstration that a mask outperforms a topical.

The individual trials are small enough to name: 55 participants, 28, 41, 35, 30 and 27 [s1]. Two of them ran for two days and four weeks respectively [s1].

Safety, so far as it has been looked at

No severe adverse reactions were reported in any of the six studies [s1]. The adverse effects that did occur were mild — dryness, erythema, or discomfort or pain during the light exposure [s1]. In one trial there were reports of acne flare in two participants (7%), dryness or itch in one (3%), facial rash in two (7%) and headache in one (3%) [s1].

The separate question about long-term light exposure to skin is whether it carries any oncologic risk. A focused systematic review examined that for photobiomodulation used in aesthetic skin rejuvenation, combining safety data from clinical trials with in-vitro data from human skin and neoplastic cells and in-vivo tumour models [s2]. Within established parameters, red and near infrared light mainly enhanced proliferation of healthy cells, mainly reduced or made no difference to neoplastic cell proliferation and viability, and did not induce dysplastic change in healthy cells [s2]. In-vivo tumour models produced varied results with no clear pattern [s2]. No relevant clinical trial data linked photobiomodulation with any significant adverse event, including new or recurrent malignancy [s2]. The review's own level-of-evidence rating for that conclusion is 4 — the lower end of the scale [s2].

The generalisability problem

The review states its limitations plainly, and the most important one is not statistical. Moderate to high heterogeneity between studies — differences in light source, fluence and treatment duration — made comparisons difficult, and the results "might not be generalizable to other devices currently on the market" [s1]. Several of the devices tested are named products from between 2011 and 2016 [s1].

That is a specific and unusual caution. In drug research a trial of 5 mg of a compound tells you about 5 mg of that compound wherever it is sold. In this field, a trial of one mask at one wavelength and one fluence does not obviously transfer to a different mask claiming the same colour of light. The review adds that publication bias may have been present despite the Egger test not detecting it, given the limited regulation of the at-home LED device market [s1].

Where it sits against the alternatives

The American Academy of Dermatology's acne guideline issued 18 evidence-based recommendations and five good practice statements, with strong recommendations for benzoyl peroxide, topical retinoids, topical antibiotics and oral doxycycline [s3]. At-home light devices are not among them. That absence reflects the size of the evidence base at the time the guideline was written rather than a judgment that the devices fail.

The review's own framing is that at-home LED devices "likely are a viable treatment option" for mild to moderate acne in people seeking non-pharmacological management, and can probably complement other treatments [s1]. That is a carefully hedged sentence, and the hedges are load-bearing.

This article is informational and is not medical advice.

Sources

• [s1] At-Home LED Devices for the Treatment of Acne Vulgaris: A Systematic Review and Meta-Analysis — JAMA Dermatology, published online 5 March 2025. https://doi.org/10.1001/jamadermatol.2025.0019
• [s2] Photobiomodulation: A Systematic Review of the Oncologic Safety of Low-Level Light Therapy for Aesthetic Skin Rejuvenation — Aesthetic Surgery Journal, published online 1 February 2023. https://doi.org/10.1093/asj/sjad018
• [s3] Guidelines of care for the management of acne vulgaris — Journal of the American Academy of Dermatology, 30 January 2024. https://doi.org/10.1016/j.jaad.2023.12.017